Assyro AI

FDA Orange Book · active-ingredient family

Pseudoephedrine hydrochloride

Pseudoephedrine hydrochloride is approved as 3 brand and 5 generic applications in the FDA Orange Book, with their therapeutic-equivalence codes, listed patents, and marketing exclusivity.

Reference-listed drug:SUDAFED 24 HOUR · NDA 020021

3

Brand (NDA)

5

Generics (ANDA)

0

Listed patents

0

Exclusivity periods

Brand (NDA) products · capsule, extended release, tablet, extended release

ProductApplicantApplicationTEApproved
SUDAFED 24 HOURRLDKENVUE BRANDSNDA 020021Dec 15, 1992
SUDAFED 12 HOURRLDGLAXOSMITHKLINENDA 017941Approved Prior to Jan 1, 1982
NOVAFEDSANOFI AVENTIS USNDA 017603Approved Prior to Jan 1, 1982

Generic (ANDA) products (5)

ProductApplicantApplicationTEApproved
PSEUDOEPHEDRINE HYDROCHLORIDEAUROBINDO PHARMA LTDANDA 218854Dec 29, 2025
PSEUDOEPHEDRINE HYDROCHLORIDEAUROBINDO PHARMAANDA 209008Jun 09, 2017
PSEUDOEPHEDRINE HYDROCHLORIDESUN PHARM INDS LTDANDA 077442Sep 28, 2005
PSEUDOEPHEDRINE HYDROCHLORIDEL PERRIGO COANDA 075153Feb 26, 1999
SUDAFED 12 HOURMCNEIL CONSANDA 073585Oct 31, 1991

Listed patents

No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.

Pseudoephedrine hydrochloride — frequently asked questions

Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

Agent CTA Background

Your Next Submission Could Take 6+ Fewer Weeks and Cost $250K Less.